Recent Updates
Recently added Catalysts
TLSI Positive Sentiment

TriSalus Life Sciences to Participate in the 38th Annual Piper Sandler Healthcare Conference on December 1, 2026

Key Takeaway: TriSalus Life Sciences will participate in the 38th Annual Piper Sandler Healthcare Conference on December 1, 2026. CEO Mary Szela and CFO David Patience will engage in one-on-one meetings and present at the event. The company aims to integrate novel medicine delivery technology with standard therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • TriSalus will present at a notable healthcare conference.
  • Management will engage in one-on-one meetings.
  • The company focuses on innovative oncology treatments.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~23 mo
Low dilution risk
Lead asset
SD-101
Phase 1 · Locally Advanced Pancreatic Adenocarcinoma

Full Press Release Details

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel medicine delivery technology with standard of care therapies to transform treatment for patients, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the Piper Sandler 38th Annual Healthcare Conference. Management will participate in one-on-one meetings and present on Tuesday

Frequently Asked Questions

When is the Piper Sandler Healthcare Conference?

The conference is scheduled for December 1, 2026.

Who will represent TriSalus at the conference?

CEO Mary Szela and CFO David Patience will represent TriSalus.

What is the focus of TriSalus Life Sciences?

TriSalus focuses on integrating novel medicine delivery technology with therapies.

Will there be one-on-one meetings at the conference?

Yes, management will participate in one-on-one meetings.

Last updated: Nov 17, 2026